Eastern Food Allergy & Comorbidity Conference 2024 (EFACC)

Palm Beach, FL US
January 4, 2024 to January 7, 2024

The 2024 EFACC activity will provide conference attendees with knowledge regarding novel food allergy developments and the expanding therapeutic armamentarium in the field of allergy, asthma and immunology, particularly as it relates to food allergy and associated allergic comorbidities. In addition to a didactic review of relevant guidelines and recent clinical studies, the format will incorporate problem-based learning (PBL), uniquely designed to interface with lectures in context to the core learning objectives relevant to the cases. By means of active discussion, learners will be challenged to formulate and justify medical decision-making concerning diagnostic and treatment strategies for patients' food allergy and comorbid allergic diseases. Topics of discussion will include food allergy prevention, food allergy immunotherapy, asthma, atopic dermatitis, eosinophilic esophagitis and shared decision making.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Eastern Food Allergy & Comorbidity Conference (EFACC)  The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 20 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 20 contact hours. 

Target Audience

Practicing allergists
Primary care physicians
Allied healthcare professionals

Learning Objectives

At the end of this activity, participants should be able to:

1. Initiate an appropriate evaluation and treatment strategy for eosinophilic esophagitis 
2. Discuss the risks and benefits of oral challenges to milk and egg
3. Compare and contrast milk and egg introduction via ladders vs. oral immunotherapy
4. Discuss quality of life and burden of illness associated with food allergy
5. Manage food allergy comorbidities including atopic dermatitis and asthma
6. Incorporate shared decision-making into food allergy management
7. Optimize anaphylaxis preparedness in food allergy

Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

Course summary
Available credit: 
  • 20.00 AMA PRA Category 1 Credit™
  • 20.00 Attendance
  • 20.00 CBRN
Course opens: 
Course expires: 
Event starts: 
01/04/2024 - 11:15am CST
Event ends: 
01/07/2024 - 12:30pm CST

Thursday, January 4

Opening Remarks, Russell Settipane, MD
1:15 – 2:00         Non-IgE-mediated Food Allergy: An Immunologic Update, Joseph A. Bellanti, MD
2:00 – 2:40         EoE:  Burden of disease, Mirna Chehade, MD
2:40 – 3:20         EoE: Diagnosis and management, Rima Rachid, MD
3:20 – 4:00         Shared decision making:  A practical guide for treatment of EoE in the world of biologics, Mirna Chehade, MD
4:00 – 4:15         Panel Discussion: Q & A
4:15 – 4:55         FPIES update: Children and adults, Shyam Joshi, MD
4:55 – 5:35         FPIES food challenge: Practical considerations, Marcus Shaker, MD
5:35 – 6:15         Allergic proctocolitis: An update on management and food introduction considerations, Shyam Joshi, MD
6:15 – 6:30         Panel Discussion: Q & A    

Friday, January 5
7:45 – 8:15        Managing food allergy in 2024: The importance of asthma control, Richard Wasserman, MD
8:15 – 8:45        Baked milk and egg introduction: Does it speed up milk/egg allergy resolution?, Anna Nowak-Wegrzyn, MD
8:45 – 10:00      PBL:  A 1-year-old with atopic dermatitis and milk allergy
                                    Ray Davis, MD, Don Bukstein, MD, Russell Settipane, MD
10:00 – 10:45    Coffee Break: Visit exhibits and posters
10:45 – 11:05    Use of mild and egg ladders: What is the evidence?, Doug Mack, MD
11:05 – 11:25    Milk and egg ladders: Patient selection, safety and shared decision making, Matthew Greenhawt, MD
11:25 – 11:45    Examples of ladders from different countries and how to use them:  A dietician’s guide on finding products for different steps, Marion Groetch, RDN
11:45 – 12:10    Baked milk and baked egg OIT, Katherine Anagnostou, MD
12:10 – 12:25    Panel Discussion: Q & A
1:20 – 1:45        OFCs to baked milk and egg: Benefits and risks, David Stukus, MD
1:45 – 3:00        Panel and post-PBL discussion: Baked milk and egg introduction:
                                   Implementation/Current evidence – Anna Nowak-Wegrzyn, MD
                                   Establishing the right setting (clinic vs at home) – Doug Mack, MD
                                   A dietitian’s guide for each step – Marion Groetch, RDN
                                   Baked OFCs: Mitigating risk – Matthew Greenhawt, MD
                                   Pearls and pitfalls – Katherine Anagnostou, MD

Saturday, January 6    
7:45 – 8:15        Incidence and prevalence of food-induced anaphylaxis: New trends, Ruchi Gupta, MD
8:15 – 8:45        Epinephrine auto-injectors for food-allergic individuals: Who, how many and when to use, Julie Wang, MD
8:45 – 10:00      PBL: A 14-year-old with asthma and milk allergy experiencing multiple episodes of anaphylaxis to accidental milk exposures, Ray Davis, MD, Don Bukstein, MD, Russell Settipane, MD
10:00 – 10:45    Coffee Break: Visit exhibits and posters
10:45 – 11:05     Anaphylaxis: Definition and criteria, Marcus Shaker, MD
11:05 – 11:25     Anaphylaxis severity scoring: How does it work?, Matthew Greenhawt, MD
11:25 – 11:45     Infant/toddler anaphylaxis and “rescue food immunotherapy”, Katherine Anagnostou, MD
11:45 – 12:10     Addressing food-related fatalities: Severe asthma and other identifiable risk factors, Jay Lieberman, MD
12:10 – 12:25    Panel Discussion: Q & A
1:20 – 1:45        How will biologics fit into the daily practical management of IgE-mediated food allergy, Rima Rachid, MD
1:45 – 3:00        Panel and post-PBL discussion: Dissecting anaphylaxis:
                                  Definition: Is it anaphylaxis? – Julie Wang, MD
                                  Predictors of severity – Katherine Anagnostou, MD
                                 When to use epi – Marcus Shaker, MD
                                 How to counsel patients – Matthew Greenhawt, MD
                                 Pearls and pitfalls in infant & toddler anaphylaxis – Jay Lieberman, MD

Sunday, January 7
8:15 – 8:45       The burden of food allergy: Co-morbidities, psychosocial and economic aspects, Ruchi Gupta, MD
8:45 – 9:15        Practical aspects of introduction of solids to the infant with eczema (PBL case), David Stukus, MD
9:15 – 9:45        A diagnostic approach to IgE-mediated food allergy (a practical algorithm), Richard Wasserman, MD
9:45 – 10:15      Identifying thresholds of reaction for different foods, Jay Lieberman, MD
10:15 – 10:45    Preparing the adolescent and the college student with food allergens: Education, advice and support, Anna Nowak-Wegrzyn, MD
10:45 – 11:15    Addressing precautionary allergen labeling: A guide, Marion Groetch, RDN
11:15 – 11:30    Panel Discussion: Q & A    

The Breakers
1 South County Road
Palm Beach, FL 33480
United States

All identified relevant financial relationships with ineligible companies have been mitigated.

Russell Settipane, MD, Planner, Speaker, Reviewer, Moderator    
AbbVie: Advisor, Speaker; Amgen: Speaker; AstraZeneca: Advisor, Speaker, Independent Contractor; BioCryst: Advisor, Speaker, Independent Contractor; Boehringer Ingelheim: Advisor, Speaker; DBV: Advisor; Genentech: Speaker; GSK: Advisor, Speaker, Independent Contractor; Grifols: Speaker; Kalvista: Advisor; Pharming: Advisor, Speaker; Pfizer: Advisor; Regeneron: Speaker, Independent Contractor; Sanofi: Speaker; Takeda: Speaker

Aikaterini Anagnostou, MD, Planner, Speaker, Moderator
Novartis: Researcher, Consultant; Genentech: Speaker, Consultant; Ready, set, food: Consultant 
William Corrao, MD, Moderator
GSK: Speaker

Robert Settipane, MD, Planner, Moderator    
Regeneron: Independent Contractor; Teva: Independent Contractor    

Don Bukstein, MD, Speaker    
Regeneron: Speaker

Mirna Chehade, MD, Speaker    
Regeneron: Consultant, Independent Contractor; Adare/Ellodi: Consultant, Independent Contractor; AstraZeneca: Consultant, Independent Contractor; Sanofi: Consultant; Bristol Myers Squibb: Consultant, Independent Contractor; Recludix Pharma: Consultant; Nexstone immunology: Consultant; Allakos: Consultant, Independent Contractor; Shire/Takeda: Independent Contractor

Ray Davis, MD, Speaker
Regeneron: Consultant; Sanofi: Consultant; Grifols: Consultant; Kalvista: Consultant

Matthew Greenhawt, MD, Speaker
Nutricia: Advisor; DBV: Advisor; Novartis: Advisor; Sanofi: Advisor; Aquestive: Advisor; Prota: Advisor; Allergy Therapeutics: Advisor; ALK-Abello: Advisor; AstraZeneca: Advisor; Bryn: Advisor; Genentech: Advisor; Paradigm Medical: Speaker; Medscape: Speaker; MJH Lifesciences: Speaker; Red Nucleus: Speaker; ImSci: Speaker; MedLearning Group: Speaker    

Ruchi Gupta, MD, Speaker
Novartis: Researcher, Consultant, Advisor; Genentech: Researcher, Consultant, Advisor; Aimmune: Consultant, Advisor; Allergenis: Consultant, Advisor
Shyam Joshi, MD, Speaker
Nectar Allergy: Advisor, Executive Role, Stocks 
Jay Lieberman, MD, Speaker
DBV: Researcher, Consultant; AbbVie: Consultant; Novartis: Speaker, Researcher, Consultant

Douglas Mack, MD, Speaker    
DBV: Advisor, Speaker, Researcher: Alladapt: Advisor; ALK-Abello: Speaker, Researcher, Consultant; Bausch Health: Advisor, Speaker   
Anna Nowak-Wegrzyn, MD, Speaker
DBV: Researcher; Nestle Sciences: Speaker; Danone Nutricia: Speaker; Siolta Therapeutics: Researcher; Thermofischer Scientific: Speaker
Labcorp: Consultant

Rima Rachid, MD, Speaker
Novartis: Researcher, Consultant; Siolta: Researcher

Ellen Sher, MD, Speaker
AbbVie: Advisor, Speaker, Consultant; AstraZeneca: Advisor, Speaker, Researcher, Consultant; Genentech: Speaker, Researcher, Consultant; GSK: Speaker, Researcher, Consultant; Incyte: Advisor; OptiNose: Speaker, Researcher; Regeneron: Speaker, Advisor, Consultant, Researcher; Novartis: Advisor, Speaker, Researcher, Consultant; Sanofi Genzyme: Advisor, Speaker, Researcher, Consultant; Allergy Therapeutics LTD: Researcher; Merck: Researcher    

Davis Stukus, MD, Speaker
DBV: Researcher

Julie Wang, MD, Speaker
UpToDate: Royalities

Richard Wasserman, MD, Speaker
Coor Pharmaceuticals: Researcher; Belhaven Biopharma: Ownership; CSL Behring: Advisor, Speaker; Elevare Consultants: Consultant; Evolve Biologics:  Consultant; Grifols: Advisor, Speaker, Researcher, Consultant; Korean Green Cross: Consultant; Takeda: Consultant, Speaker, Researcher; GSK: Speaker 

The following have no relevant financial relationships with ineligible companies to disclose:

Joseph A Bellanti, MD, Speaker
William Greisner, MD, Planner, Moderator
Katelyn Loiselle, RN, Planner     
Ginny Loiselle, Coordinator       
Sally Bailey, MD, Speaker
Marion Groetch, MD, Speaker
Marcus Shaker, MD Speaker

Available Credit

  • 20.00 AMA PRA Category 1 Credit™
  • 20.00 Attendance
  • 20.00 CBRN
Please login or create an account to take this course.